Our results demonstrate a potential role of glycolytic enzymes in beiging of visceral WAT and suggest that PGAM1 would be a novel therapeutic target in obesity and diabetes. The gene discussed is PGAM1; the disease is obesity due to melanocortin 4 receptor deficiency.